Report from: India

Wan, Jane
June 2012
Pharmaceutical Technology;Jun2012, Vol. 36 Issue 6, p18
Trade Publication
The article reports on the strict drug pricing plan of Indian government for its domestic pharmaceutical market. It says that the proposed policy requires at least 400 essential drugs to be under the National List of Essential Medicines (NLEM) and increases the government control to drugs for up to 70%. It adds that the plan of the government to base the ceiling prices of products on the biggest sellers of individual therapeutic group was questioned by the World Health Organization (WHO).


Related Articles

  • Medicine prices, availability and affordability in Sri Lanka. Ganga Senarathna, S. M. D. K.; Mannapperuma, Uthpali; Rohini Fernandopulle, B. M. // Indian Journal of Pharmacology;Feb2011, Vol. 43 Issue 1, p60 

    Background: No pricing formula has been implemented from November 2002 to date in Sri Lanka. Therefore, we initiated a study in 2003 to determine the prices, availability and affordability of medicines in the private sector of Sri Lanka in the absence of a price control. Materials and Methods:...

  • 80% of Medicines not covered by Price control order.  // IDA Times;Jan2014, Vol. 10 Issue 1, p16 

    The article informs that the drug price control order (DPCO) 2013, meant to control medicine prices in India, does not cover over 80 percent of the medicines in the market, as of January 2014. Topics discussed include a 2013 Indian Supreme Court case on National Pharmaceutical Pricing Policy...

  • Nominal prices come under scrutiny. Gebhart, Gred // Drug Topics;6/20/2005, Vol. 149 Issue 12, DRUG TOPIC FOR THE HEALTH-SYSTEM p 

    This article focuses on issues related to the practice of nominal pricing in the U.S. According to pharmacist David Chen, who directs ASHP's section of home, ambulatory, and chronic care practitioners, a healthy percentage of facilities make use of nominal pricing. It can have a significant...

  • Price controls and new medicines do not go together. Helms, Elizabeth // Business Journal Serving Fresno & the Central San Joaquin Valley;03/20/2000, Issue 322592, p35 

    Comments on the United States government's plan to implement health care mandates that could restrict access to prescription drugs. Negative effects of the implementation of price controls on drugs; Senior citizens' right to enroll in a pharmaceutical coverage plan of their choosing; Call for a...

  • International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Gross, David J.; Ratner, Jonathan; Perez, James; Glavin, Sarah L. // Health Care Financing Review;Spring94, Vol. 15 Issue 3, p127 

    Compares prescription drug spending control policies in France, Germany, Sweden and Great Britain. Drug prices and affordability; Drug manufacturer regulations; Product-by-product price controls; Limits on insurer reimbursement prices; Profit controls; Manufacturer pricing regulation effects;...

  • New pricing policy for drugs in India.  // PharmacoEconomics & Outcomes News;5/25/2013, Issue 679, p11 

    The article reports on the release of the drug price control order (DPCO) which would result to a decrease of prices of 348 essential drugs in India effective May 15, 2013.

  • Huge Sellers' Herald Changes in Japan Drug Pricing. Macarthur, Donald // Pharmaceutical Executive Global Digest;Oct2016, Vol. 36 Issue 10, p40 

    The article discusses the increase of prescription drug sales in Japan in 2015, the introduction of mandatory cost-effectiveness standards and the revision of pricing rules of drugs targeting those marketed drugs considered as huge sellers including Opdivo and Repatha.

  • How Parallel Trade Affects Drug Policies and Prices in Canada and the United States. Hollis, Aidan; Ibbott, Peter // American Journal of Law & Medicine;2006, Vol. 32 Issue 2/3, p193 

    The article examines how parallel trade affects drug policies and prices in Canada and the U.S. U.S. consumers and Canadian pharmacies have taken advantage of the opportunity presented by price differences in patented pharmaceuticals. This brought the Canadian and U.S. systems for determining...

  • Beware of Drug-Price Controls. Edwards, Gregg M. // njbiz;11/27/2006, Vol. 19 Issue 48, p12 

    The author warns about the impending drug-price control being ushered by the new leadership in the U.S. Congress in November 2006. The newly elected leadership in Congress is set to change Medicare's drug-benefit program by requiring the U.S. federal government to directly negotiate drug prices...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics